Trace Neuroscience, Inc.

About Trace Neuroscience, Inc.

Trace Neuroscience is a biotech company focused on developing breakthrough treatments for neurodegenerative diseases, particularly ALS (amyotrophic lateral sclerosis). Their mission is to expand the promise of genetic medicine to a broader population of ALS patients by restoring UNC13A protein function to improve nerve and muscle communication.

Products & Services

UNC13A Restoration Therapy:A lead program using antisense oligonucleotides (ASO) to correct UNC13A mRNA splicing, aiming to restore synaptic function in ALS patients, targeting 97% of those with TDP-43 mislocalization.

Specialties

Neurodegenerative Diseases ALS (Amyotrophic Lateral Sclerosis) Genetic Medicine UNC13A Protein Restoration Antisense Oligonucleotides (ASO)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 101000000 MR: - FA: $101 million FAN: 101000000	D: 2024-11-12 FD: 2024-11-12	4 investors

Series A Latest

2024-11-12

$101.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Precillia Redmond

Chief People Officer

LinkedIn (Pro only)

N

Nick Mordwinkin

Chief Business Officer & Chief Strategy Officer

LinkedIn (Pro only)

M

Marjie L. Hard

SVP, Development Sciences

LinkedIn (Pro only)

E

Eric Green, M.D., Ph.D.

Chief Executive Officer

M

Megan Baierlein

Chief Operating Officer

I

Irina Antonijevic

Chief Medical Officer

View 18 more team members with Pro

Unlock Full Team Directory

Recent News